Fate Therapeutics (FATE)
1.90
-0.01 (0.52%)
Upcoming Events
Latest Headlines
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
June 8, 2026 9:01 AM - Globe NewsWire
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
June 8, 2026 9:01 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Fate Therapeutics (FATE)
June 8, 2026 6:58 AM - StreetInsider
Form 8-K FATE THERAPEUTICS INC For: Jun 04
June 4, 2026 4:37 PM - SEC Filing
Fate Therapeutics reports trial data on autoimmune treatments
June 4, 2026 8:32 AM - StreetInsider
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
June 4, 2026 8:30 AM - StreetInsider
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 2, 2026 4:05 PM - StreetInsider
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
June 1, 2026 8:30 AM - StreetInsider
Form 4 FATE THERAPEUTICS INC For: May 20 Filed by: TAHL CINDY
May 21, 2026 4:03 PM - SEC Filing
Form 4 FATE THERAPEUTICS INC For: May 20 Filed by: Valamehr Bahram
May 21, 2026 4:01 PM - SEC Filing
Fate Therapeutics to present CAR T-cell therapy data at medical conferences
May 21, 2026 8:32 AM - StreetInsider
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
May 21, 2026 8:30 AM - StreetInsider
Form 144 FATE THERAPEUTICS INC Filed by: Valamehr Bahram
May 20, 2026 3:41 PM - SEC Filing
Form 144 FATE THERAPEUTICS INC Filed by: TAHL CINDY
May 20, 2026 3:39 PM - SEC Filing
Jefferies Assumes Fate Therapeutics (FATE) at Buy
May 19, 2026 3:11 PM - StreetInsider
Form 10-Q FATE THERAPEUTICS INC For: Mar 31
May 13, 2026 8:34 AM - SEC Filing
Form 8-K FATE THERAPEUTICS INC For: May 13
May 13, 2026 8:32 AM - SEC Filing
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
May 13, 2026 8:30 AM - Globe NewsWire
Fate Therapeutics reports clinical progress for FT819 lupus treatment
May 11, 2026 8:31 AM - StreetInsider
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
May 11, 2026 8:30 AM - Globe NewsWire
Form 4 FATE THERAPEUTICS INC For: May 06 Filed by: TAHL CINDY
May 7, 2026 4:01 PM - SEC Filing
Form 4 FATE THERAPEUTICS INC For: May 05 Filed by: EPSTEIN ROBERT S
May 6, 2026 4:02 PM - SEC Filing
Form 4 FATE THERAPEUTICS INC For: May 05 Filed by: RASTETTER WILLIAM H
May 6, 2026 4:00 PM - SEC Filing
Fate Therapeutics selected for FDA manufacturing pilot program
May 5, 2026 8:31 AM - StreetInsider
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819
May 5, 2026 8:30 AM - Globe NewsWire
Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
May 4, 2026 9:00 AM - StreetInsider
Fate Therapeutics (FATE) PT Raised to $7 at H.C. Wainwright
May 4, 2026 7:28 AM - StreetInsider
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
May 1, 2026 4:05 PM - StreetInsider
Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting
April 30, 2026 9:00 AM - StreetInsider
Form ARS FATE THERAPEUTICS INC For: Dec 31
April 24, 2026 4:11 PM - SEC Filing
Form DEFA14A FATE THERAPEUTICS INC
April 24, 2026 4:10 PM - SEC Filing
Form DEF 14A FATE THERAPEUTICS INC For: Jun 12
April 24, 2026 4:04 PM - SEC Filing
Form 4/A FATE THERAPEUTICS INC For: Apr 20 Filed by: Redmile Group, LLC
April 23, 2026 9:00 PM - SEC Filing
Form 4 FATE THERAPEUTICS INC For: Apr 20 Filed by: Redmile Group, LLC
April 22, 2026 9:52 PM - SEC Filing
Form SCHEDULE 13D/A FATE THERAPEUTICS INC Filed by: Redmile Group, LLC
April 22, 2026 9:47 PM - SEC Filing
Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without
April 16, 2026 11:45 AM - Globe NewsWire
Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without
April 16, 2026 9:01 AM - StreetInsider
Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences
April 9, 2026 9:00 AM - StreetInsider
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
April 2, 2026 4:05 PM - StreetInsider
Form SCHEDULE 13G/A FATE THERAPEUTICS INC Filed by: VANGUARD GROUP INC
March 26, 2026 6:21 PM - SEC Filing
Mizuho on Fate Therapeutics (FATE): 'setting up as a key year for the story'
March 24, 2026 3:04 PM - StreetInsider
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed
March 18, 2026 11:30 AM - StreetInsider
Full Article List
